(Q44439073)

3 December 2017

title

A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma (English)

1 reference

3 December 2017

1 reference

Della Makower

1

1 reference

3 December 2017

Joseph A Sparano

2

1 reference

3 December 2017

Scott Wadler

3

1 reference

3 December 2017

Karen Fehn

4

1 reference

3 December 2017

Leon Landau

5

1 reference

3 December 2017

Paul Wissel

6

1 reference

3 December 2017

Melissa Versola

7

1 reference

3 December 2017

Sridhar Mani

8

1 reference

3 December 2017

publication date

1 April 2003

1 reference

3 December 2017

1 reference

3 December 2017

volume

21

1 reference

3 December 2017

issue

2

1 reference

3 December 2017

page(s)

177-184

1 reference

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016413

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016413

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016413

Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016413

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016413

Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016413

The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016413

Edrecolomab (monoclonal antibody 17-1A)

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016413

Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016413

Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016413

Phase I Trial of Multiple Large Doses of Murine Monoclonal Antibody CO17-1A. I. Clinical Aspects1

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120016413

21 January 2018

Identifiers

DOI

10.1081/CNV-120016413

1 reference

3 December 2017

1 reference